

# CURRICULUM VITAE

Nancy Jean M. Vuckovich Bohannon, MD, FACP, FACE

Home address: 160 Dorado Terrace  
San Francisco, CA 94112  
(415) 584-6155

Business Address: Monteagle Medical Center  
1580 Valencia Street, Suite 504  
San Francisco, CA 94110  
(415) 648-7622

Tax I.D. Number 94-2534677

Academic Title: Director of Clinical Research  
Cardiovascular Risk Reduction  
Program, Saint Luke's Hospital,  
San Francisco, CA

Birthplace: Cherry Point, North Carolina  
Date: November 25, 1947

Personal:  
Married Richard Anderson Bohannon MD, 1/19/74  
Child Robert John Bohannon, born 7/22/78

Education:  
1965 - 1966 California State College at Fullerton  
Fullerton California

1966 - 1968 University of Illinois (Champaign-Urbana)  
Urbana, Illinois  
BS with Honors

1968-1970 Student Work-Study Program  
Animal Cancer Research  
University of California Veterinary School,  
Davis, California

1971 American Cancer Society Student  
Fellowship.  
Cancer Research Institute  
University of California, San Francisco

1968 - 1972 University of California  
Davis, California  
M.D.

Postgraduate Training:

1972 - 1973	Internship:	Straight Internal Medicine Children's Hospital, San Francisco, CA
1973 - 1974	Residency:	Internal Medicine Children's Hospital, San Francisco, CA
1974- 1975	Fellowship:	San Francisco Diabetes Association Clinical Fellowship Metabolic Research Unit University of California, San Francisco, CA
1975 - 1976	Fellowship:	Dorothy Frank Research Fellowship of San Francisco Diabetes Association. Metabolic Research Unit University of California, San Francisco

University Faculty Appointments:

1978-1992	Assistant Clinical Professor, UCSF
1992-1998	Associate Clinical Professor of Medicine and Family and Community Medicine, UCSF
1991-present	Adjunct Assistant Professor of Medicine, Baylor College of Medicine

Professional Organizations:

American Medical Association, 1976-present

California Medical Association

- 1) Delegate to the California Medical Association 1982-1985
- 2) Member, Committee on Scientific Assembly 1981-1987
- 3) Chairman, Committee on Scientific Assembly 1983-1987
- 4) Member, Scientific Board of California Medical Association 1983-1987
- 5) Member, Reference Committee on Federal Health Care Issues, 1981, 1982

San Francisco Medical Society

- 1) Board of Directors 1982-1984
- 2) Speaker's Bureau for Health Related Matters 1980-Present
- 3) Member, Administrative Board of Directors, Irwin Memorial Blood Bank 1982-84

American College of Physicians

Associate, 1976-1981

Member since 1981

Fellow since 1984

American Society of Internal Medicine, member 1974-present

Skyline Medical Association, member 1988-, Exec. comm. 1993-1997, President-elect 1994,  
President 1995

California Society of Internal Medicine

- 1) Delegate to Annual Meeting 1978, 1980, 1982, 1984, 1986, 1988, 1989, 1997
- 2) Membership Committee 1981-1983
- 3) Annual Meeting Local Arrangements Committee, 1988

San Francisco, Society of Internal Medicine

- 1) Council Member 1978-1992
- 2) Secretary-Treasurer 1981-1982
- 3) President 1983-1984

American Diabetes Association  
Professional Section 1978-Present  
California Affiliate  
1) Chairman, Committee on Public Education, 1987-1989  
San Francisco Chapter  
1) Member, Board of Directors 1976-1980  
2) Vice President 1979  
3) Advisory Board 1982  
4) Speaker's Bureau 1976-Present  
5) President 1989

Northern California Professional Diabetes Association 1978-Present  
1) Vice President 1983

Diabetes Travel Service (Member of the Board).  
American Federation for Clinical Research, Member 1982-Present  
Peripheral Neuropathy Institute, Member 1990  
International Diabetes Federation 1991-present  
American Heart Association Council on Arteriosclerosis 1991  
Association of Insulin Pump Therapy 1991  
National Grave's Disease Foundation 1991  
American Association of Clinical Endocrinologists, Member 1992-  
Institute for Circus Medicine, Member 1992-  
National Lipid Education Council, Member 1996-

Related Activities:

Tumor Board, Children's Hospital of San Francisco 1972-1974  
Physician, Bearskin Meadow Diabetic Children's Camp 1974  
Diabetes Clinic, San Francisco General Hospital 1974-1976  
Diabetes Youth Group, Director, San Francisco, California 1974-1976  
Diabetes Clinic, University of California at San Francisco 1974-1987  
Episcopal Chaplaincy of San Francisco General Hospital (Board of Directors) 1979-1981  
St. Luke's Hospital, San Francisco, California  
1) Endocrine Clinic 1976-1980  
2) Diabetes Clinic 1976-1977  
3) Diabetes Outreach Committee, (Chairman 1978) Member 1978-Present  
4) Total Parental Nutrition Committee, (Chairman, 1983-1985) Member 1980-1985  
5) Utilization Review Committee 1976-1981  
6) Reporter to San Francisco Medicine from St. Luke's Hospital, 1982-1984  
7) Medical Staff Parliamentarian, 1983-1984  
8) Institutional Review Board 1985-1996  
9) Drug Audit Subcommittee Member 1985-1990  
10) Library/C.M.E. Committee Member 1985-Present  
11) Nominating Committee Member 1987  
12) Art Committee 1988-1990

Bay Pacific Health Plan IPA (Board of Directors, Chairman Membership Committee,  
Ambulatory Care Committee), 1980-1982  
Medical Education Association for Cultural Aspects of Health Care  
Permanent Medical Faculty, 1978-Present  
Pan American Medical Society, Member 1978-Present  
Coalition for the Preservation of Private Practice, Member 1979-Present  
Consultant to the Ministry of Health, Abu Dhabi, United Arab Emirates, 1995-Present

Editorial and Review Boards:

Reviewer for Expert Opinion on Pharmacotherapy-2003  
Reviewer for Patient Care (Diabetes Case and Comment) 1985-Present  
Editorial Review Panel, Postgraduate Medicine, 1987-Present  
Editorial board of Diabetes Forecast, January 1993-December 1995.  
Professional Advisory Panel, Patient Care, 1994.  
Reviewer for American Society of Health System Pharmacists Drug Information, 1996-97  
Editorial Board for Primary Care Reports: The Practical Journal for Family Physicians, 1996-Present.  
Reviewer for Endocrine Practice, 1998-Present  
Editorial Advisory Board for American Health Consultants: Diabetes Management, 1998-

Reviewer for Diabetes Care, 1999-present  
Reviewer for Clinician Review, 2002  
Reviewer for Diabetes and It's Complications, 2004  
Member of Diabetes Trust Foundation Medical and Scientific committee, 2004-  
Reviewer for Expert Review of Medical Devices, 2004  
Editorial board member for Insulin, 2005-present

#### PUBLICATIONS:

1. Klock J, and Vuckovich N.: Current Status of Bone Marrow Transplantation. Oncology 29: 127-151, 1974.
2. Gerich JE, Tsalikian E, Lorenzi M, Schneider V, Bohannon NJ, Gustafson G, and Karam JH: Normalization of Fasting Hyperglucagonemia and Excessive Glucagon Responses to Intravenous Arginine in Human Diabetes Mellitus by Prolonged Infusion of Insulin. J. Clin. Endocrinol. Metab. 41: 1178-1180, 1975.
3. Bohannon NJ, Lorenzi M, Gerich HD, and Karam, JH: Plasma Glucagon Suppression by Phenformin in Man. Diabetes 24 (Suppl. 2): 428, 1975.
4. Lorenzi M, Bohannon NJ, Tsalikian E, Hane S, Gerich JE, Karam JH, and Forsham PH.: Intact Dopaminergic Receptors for Growth Hormone and Prolactin Secretion in Insulin-Dependent Diabetics. Clinical Research 24: 110A, 1976.
5. Gerich J, Lorenzi M, Tsalikian E, Schneider V, Bohannon NJ, Karam JH, and Forsham PH: Selective Pancreatic A-cell Insensitivity to Glucose in Human Diabetes Mellitus: Evidence for a Defective Glucoreceptor. Clinical Research 24: 155A, 1976.
6. Bohannon NJ, Karem J, Lorenzi M, Gerich J, and Forsham P.: Plasma Glucagon Levels After Tolbutamide or Phenformin in Insulin-Dependent Diabetics. Clinical Research 24: 154A, 1976.
7. Lorenzi M, Tsalikian E, Bohannon NJ, Gerich JE, Karem JH, and Forsham PH: Evidence Against Dopaminergic Modulation of Glucagon and Insulin Release in Man. Program of the 58th Annual Meeting of the Endocrine Society, San Francisco, California, June 23-25, 1976, p. 229.
8. Meyer EJ, Lorenzi M, Bohannon NJ, Amend W, Feduska JH, Salvatierra O, and Forsham PH: Use of Insulin Infusion in Diabetic Renal Transplantation. Program of the 57th Annual Meeting of the American College of Physicians, Philadelphia, Pennsylvania, April 5-8, 1976 (Abstract No. 11).
9. Lorenzi M, Tsalikian E, Bohannon NJ, Gerich JE, Karam, JH, and Forsham PH: Differential Sensitivity of Pancreatic Glucagon to L-Dopa and Apomorphine in Man: Evidence Against a Direct Dopaminergic Mechanism of Stimulation. Program of the 5th International Congress of Endocrinology, Hamburg, Germany, July 18, 1976: 24: 341.
10. Gerich JE, Lorenzi M, Tsalikian E., Bohannon NJ, Schneider V, Karam JH, and Forsham PH: Effects of Acute Insulin Withdrawl and Administration of Plasma Glucagon Responses to Intravenous Arginine in Insulin-Dependent Diabetic Subjects. Diabetes 25: 855-960, 1976.
11. Gerich J, Lorenzi M, Tsalikian E, Bohannon NJ, Brooks R, Meyer J, Schultz T, Spencer M, and Forsham PH: Prolonged Intravenous and Subcutaneous Somatostatin in Treatment of Human Diabetes. Diabetes 25 (Suppl. 1): 340, 1976.
12. Tsalikian E, Dunphy T, Bohannon NJ, Lorenzi M, Gerich J, and Karam JH: Suppression of Plasma Glucagon During Chronic Sulfonylurea Therapy in Adult-Onset Diabetes. Diabetes 25 ( Supplement 1): 387, 1976.

13. Tsalikian E, Dunphy TW, Bohannon NJ, Lorenzi M, Gerich JE, Forsham PH, Kane JP, and Karam JH: The Effect of Chronic Oral Antidiabetic Therapy on Insulin and Glucagon Responses to a Meal. Diabetes 26: 314-321, 1977.
14. Goldberg ML, Bohannon NJ, Brooks RM, Tsalikian E, Lorenzi M, and Forsham, PH: The Effects of Insulin and Hyperglycemia on Plasma Cyclic Nucleotide Levels in Juvenile Onset Diabetes. Diabetes 26: 936-943, 1977.
15. Bohannon NJ, Karam JH, Lorenzi M, Gerich JE, Matin SB, and Forsham PH: Plasma Glucagon Suppression by Phenformin in Man. Diabetologia 13: 503-508, 1977.
16. Lorenzi M, Tsalikian E, Bohannon NJ, Gerich JE, Karam JH, and Forsham PH: Differential Effects of L-Dopa and Apomorphine on Glucagon Secretion in Man. J. Clin. Endocrinol. Metab. 45: 1154-1158, 1977.
17. Gerich J, Davis J, Lorenzi M, Bohannon NJ, and Cryer P: Interaction of Catecholamines and Glucagon in Glucose Counterregulation. Diabetes 26 (Supplement 1) 384, 1977.
18. Lorenzi M, Schmitt JK, Bohannon NJ, Tsalikian E, Karam JH, and Forsham PH: Intravenous Dopamine Stimulates Growth Hormone Secretion in Diabetic Subjects: A Clue to Blood-Brain Barrier Abnormalities. Diabetes 26 (Suppl. 1): 378, 1977.
19. Lorenzi M, Tsalikian E, Bohannon NJ, Schmitt J, Gerich J, and Karam JH: Dopamine During Alpha-and-Beta-Adrenergic Blockade in Man: Effect of Plasma Glucagon, Insulin, Prolactin, and Growth Hormone. Program of the 59th Annual Meeting of the Endocrine Society, Chicago, Illinois, June 8-10, 1977, P. 135.
20. Feldman EC, Bohannon NJ, and Tyrrell JB: Plasma Adrenocorticotropin Levels in Normal Dogs. American Journal of Veterinary Research 38: 1643-1645, 1977.
21. Bohannon NJ, Karam JH, and Forsham PH: Comparison of Prolonged Responses to Fructose, Sucrose, and Glucose Feeding. Presented at the Annual Meeting of the American Diabetic Association, Los Angeles, California, October 11, 1977. (Program, p. 20).
22. Schmitt J, Lorenzi M, Gerich H, Bohannon NJ, Karam JH, and Forsham PH: Effect of Phentolamine on Somatostatin's Action in Man. Clinical Research 26: 131A, 1978.
23. Lorenzi M, Schmitt J, Tsalikian E, Bohannon NJ, Gerich J, Karam JH, and Forsham PH: Dose-Response Curves for Insulin and Glucagon Suppression by Somatostatin in Man. Clinical Research 26: 159A, 1978.
24. Bohannon NJ, Karam JH, and Forsham PH: Advantages of Fructose Ingestion Over Sucrose and Glucose in Humans. Presented at the Annual Meeting of the American Diabetes Association, Boston, Massachusetts, June, 1978. Diabetes 27 (Supplement 2): 438, 1978.
25. Lorenzi M, Karam JH, Tsalikian E, Bohannon NJ, Gerich JE, and Forsham PH: Dopamine During Alpha- and Beta-Adrenergic Blockade in Man: Hormonal, Metabolic and Cardiovascular Effects. J. Clin. Invest. 63:310, 1979.
26. Schmitt J, Bohannon NJ, Burns A, and Forsham PH: Comparative Effects of Indomethacin and Ibuprofen on the Response of Arginine in Man. Diabetes 28: 440, 1979.
27. Meyer EJ, Lorenzi M, Bohannon NJ, Amend W, Feduska NJ, Salvatierra O, and Forsham PH: Diabetic Management by Insulin Infusion During Major Surgery. American Journal of Surgery 137: 323, 1979.

28. Schmitt JK, Lorenzi M, Gerich JH, Bohannon NJ, Karam JH, and Forsham PH: Phentolamine and the Action of Somatostatin in Man. J. Clin. Endocrinology Metab. 48:880, 1979.
29. Bohannon NJ, Karam JH, and Forsham PH: Endocrine Responses to Sugar Ingestion in Man. J. Am. Dietetic Assn. 76:6, 1980.
30. Gerich J, Davis J, Lorenzi M, Rizza R, Bohannon NJ, Karam JH, Lewis S, Kaplan R, Schultz T, and Cryer P: Hormonal Mechanisms of Recovery from Insulin-Induced Hypoglycemia in Man. Am. J. Physiol. 236 (4), E380, 1979.
31. Deftos LJ, Lorenzi M, Bohannon NJ, Tsalikian E, Schneider V, and Gerich JE: Somatostatin does not suppress Plasma Parathyroid Hormone. J. Clin. Endocrinol. Metab. 43: 205, 1976.
32. Schmitt JK, Bohannon NJ, Lorenzi M, Karam JH, and Forsham PH: Arginine-Stimulated Fall in Free Fatty Acids as an Index of Insulin Reserve in Diabetics. Clinical Research 28: 26A, 1980.
33. Schmitt JK, Bohannon NJ, Karam JH, Forsham PH: Arginine-Stimulated Fall in Free Fatty Acids as an Index of Insulin Reserve in Diabetics. Diabetes 29: 68A, 1980.
34. Bohannon NJ: Anabolic Steroid Abuse and Impotence. Medical Aspects of Human Sexuality. 14: 60, 1980.
35. Klonoff DC, Young CW, Chan ETY, Burns A, Bohannon NJ, Karam JH, Forsham PH: Advantages of Fructose as a Dietary Sweetener in Insulin-Dependent Diabetes. Clin. Res. 29 (1): 55A, 1981.
36. Bohannon NJ, Reitz RE, Hauer SD, Wang CA: The Management of Acute Hyperparathyroidism in the Community Hospital. JAMA: 246 (12) 1334, 1981.
37. Bohannon NJ, Zilbergeld BV, Bullard DG, and Stoklosa JM: Treatable Impotence in Diabetics. Western Journal of Medicine 136: 6-10, 1982.
38. Bohannon NJ, Karam JH, Grodsky GM: Stimulatory Effects of Tolbutamide Infusion on Plasma Glucagon in Insulin-Dependent Diabetic Subjects. J. Clin. Endo and Metab. 54:459-462, 1982.
39. Bohannon NJ: Newer Forms of Insulin. West J. Med. 139: 115-116, 1983.
40. Bohannon NJ: Anorexia Nervosa. J. Osteo. Med. 1: 28-36, 1987.
41. Bohannon NJ: Large Phosphate Shifts During Therapy for Hyperglycemia. presented at Northern California Annual Meeting of American College of Physicians, Monterey, California, Oct.18,1987.
42. Bohannon NJ, Torfs CP, van den Berg BJ, Okerlund MD: Thyroid Disease in Families of Proband with IDDM. Presented at International Diabetes Federation meeting, Sydney, Australia 11/88.
43. Torfs CP, van den Berg BJ, Bohannon NJ, Caro MB, Okerlund MD: Lack of Spouse Concordance for Thyroid Antibodies Suggests that Shared Environmental Factors have no Effect on the Expression of Autoimmune Thyroid Diseases. Submitted.
44. Bohannon NJ: Diabetes in the Elderly. Postgraduate Medicine. 84: 283-295, 1988.
45. Bohannon NJ: Gestational Diabetes. Diabetic Management Issues for the Educator. Synopses of Selected Presentations. AADE, Dallas

46. Bohannon NJ: Hypophosphatemia in Treatment of Hyperglycemia. Archives of Internal Medicine 149:1423-1426, 1989.
47. Bohannon NJ: Diabetes Control and the Drugs That Can Disturb It, Senior Patient. May 33-36, 1990.
48. Bohannon NJ: Diabetes and Calcium Channel Blockers (letter), Senior Patient, August 57-58, 1990.
49. Bohannon NJ: Diabetic Ketoacidosis Triggered by Typhoid Fever in a Type II Diabetic, Infections in Med 9: 45-52, 1992.
50. Bohannon NJ: Lipid Metabolism in Type II Diabetes, Postgraduate Medicine 92:105-113, 1992.
51. Bohannon NJ ed, Davidson MB, Riddle MC: Symposium on Non-Insulin Dependent Diabetes Mellitus, Postgraduate Medicine 92: 69-113, 1992
52. Bohannon NJ: Effective Use of Insulin, Postgraduate Medicine 95: 52-67, 1994.
53. Bohannon NJ: Type II Diabetes, Primary Care Reports 1(9): 65-74, May 1995.
54. Torfs CP, Bohannon NJ, van den Berg BJ: Spousal Concordance of Autoimmune Thyroid Disease (submitted to Endocrine Practice, 1995)
55. Tomada JA, Bohannon NJ, Potts R: Measurement of Blood Glucose in Diabetic Subjects Using Non-invasive Transdermal Extraction , Nature Medicine, 1 (11): 1198-1201, November, 1995.
56. Bohannon NJ: Type II Diabetes : Tips For Managing Your Older Patients, (Part 1) Geriatrics, 51 (3): 28-35, March 1996.
57. Bohannon NJ: Type II Diabetes : Tips For Managing Your Older Patients, (Part II) Geriatrics, 51 (4): 28-35, April 1996.
58. Bonow R O, Bohannon NJ, Hazzard W: Risk Stratification in Coronary Artery Disease and Special Populations, American Journal of Medicine 101 (Supp. 4A): 17S-24S, 1995.
59. Winslow E, Bohannon NJ, Brunton SA, Mayhew HE : Lifestyle Modification: Weight Control, Exercise, and Smoking Cessation , American Journal of Medicine 101 (Supp. 4A): 25S-33S, 1996.
60. Bohannon NJ: Benefits of Lispro Insulin , Postgraduate Medicine 101 (2):73-80, 1997.
61. Faro S, Apuzzio J, Bohannon NJ, Elliott K, Martens MG, Mou SM, Phillips-Smith LE, Soper DE, Strayer A, Young RL: Treatment Considerations in Vulvovaginal Candidiasis, The Female Patient, 22, March 1997
62. Bohannon Nancy JV: Management of Vulvovaginal Candidiasis in the Diabetic Patient, Diabetes Care 21 (3): 451-456, 1997
63. Ginsberg B, Bohannon N, et. al: In Vivo Studies of a Non-Invasive Glucose Monitor in Patients with Diabetes (abstract presented) American Diabetes Assn. meeting, June, Diabetes, 1998
64. Bohannon, Nancy J.V.: Coronary Heart Disease and Diabetes, Postgraduate Medicine 105(2):65-80, 1999.
65. Bohannon N: Insulin Delivery Using Pen Devices, Postgraduate Medicine 106 (5):57-68, 1999.
66. Bohannon N, Streja L.; Effectiveness of Terbinafine Therapy for Toenail Onychomycosis in Persons with Diabetes (abstract presented American Diabetes Association meeting, June 2000) 49 (S1):805P, 2000.

67. Feldman B, McGarraugh G, Heller A, Bohannon N, Skyler J, DeLeeuw E, Clarke M : FreeStyle: A Small-Volume Electrochemical Glucose Sensor for Home Blood Glucose Testing, Diabetes Technology & Therapeutics Vol 2 (2):221-229, 2000
68. Bohannon NJ, Fishman I: Comparison of Efficacy and Patient Preference for Lispro versus Humulin Regular Insulin and Delivery by a 1.5 mL Pen Injection Device (in preparation 1999)
69. Bohannon NJ, Ohannesian JP, Burdan AL, Holcombe JH, Zagar A: Patient and Physician Satisfaction with the Humulin®/Humalog® Pen, a new 3.0-mL Prefilled Pen Device for Insulin Delivery, Clinical Therapeutics Vol 22, No 9 (1049-1067), 2000
70. Bohannon NJ: Type 1 versus type 2 diabetes still a useful distinction? Postgraduate Medicine 100(2):23-24, 2001
71. Bohannon NJ: Treating dual defects in diabetes: Insulin resistance and insulin secretion American Journal of Health-System Pharmacy™ Vol 59, Supplement 9 (9-13), December 1, 2002
72. Bohannon NJ: Optimizing insulin regimens in type 1 diabetes Postgraduate Medicine, Vol.113, No.6 (39-54), June 2003
73. Quattrin T, Belanger A, Bohannon N, Schwartz S: Efficacy and Safety of Inhaled Insulin (Exubera) Compared to Subcutaneous Insulin Therapy in Patients with Type 1 Diabetes: Results of a 6-month Randomized, Comparative Trial Diabetes Care, Vol. 27:2622-2627, 2004
74. Bohannon N: Insulin Therapy for Reducing Cardiovascular Risk in Patients with Type 2 Diabetes, Clinical Cornerstone, Supp.4, S21-27, November 2003
75. Bohannon N: Targeting pre and Post prandial Glucose Levels in Clinical Practice, Type 2 Diabetes Digest, Volume 8, No. 4, November 2004
76. Deepak L, Steg G, Ohman E, et al: International Prevalence, Recognition, and Treatment of Cardiovascular Risk Factors in Outpatients With Atherothrombosis, JAMA, Vol. 295, No.2, Jan 11, 2006. (Contributing author: Nancy Bohannon)

#### RESEARCH AND CLINICAL TRIALS

1. Evaluation of Human Insulin, Eli Lilly, 1982 - 1983, Phase III.
2. Human Insulin Clinical Trials Prior to Release, 1983, Phase III.
3. Evaluation of Cimetidine on Parathyroid Hormone and Calcium Levels in Normal Control Population, 1983 - 86.
4. The Efficacy and Safety of Glipizide in Patients with Non-Insulin Dependent Diabetes Mellitus Previously Treated with Insulin, 1984-85, Phase IV.
5. Study of Cimetidine in Hyperparathyroidism  
Collaborating with Janice Sherwood, M.D., 1983 - 87.
6. Islet Cell Antibodies in 1st Degree Relatives of Type I Diabetics  
Collaborating with George Eisenbarth MD, Joslin Clinic, and Stuart Soeldner MD,  
Univ. of Calif./Davis, 1984 - present.
7. Study of Autoimmune Antibodies in Families of patients with Autoimmune Thyroid Disease or Type I Diabetes  
Collaborating with Claudine Torfs PhD, Berkeley, and William Riley MD,  
Univ. of Florida, 1985 - present.
8. Study of Thyroid Antibodies in Conjugal Couples.  
Collaborating with Claudine Torfs, PhD, 1985 - present.
9. Study of Antithyroid Antibodies in Families With Type I Diabetics  
Collaborating with Claudine Torfs, PhD, 1985 - present.
10. Study of Thyroid Antibodies in Families With Thyroid Disease  
Collaborating with Claudine Torfs, PhD, 1985 - present.
11. Glucotrol Post-Introduction Evaluation, 1985, Phase IV.
12. Sorbinyl Aldose Reductase Inhibitor In Diabetic Complications,  
1985 - 1987 (compassionate protocol).
13. Tenoretic Evaluation Program: A Study in Post-Introduction

- Surveillance of a New Antihypertensive Drug, January, 1986, Phase IV.
14. One Touch Early Trials Program, May 1988.
  15. Cholestech evaluation of LDX HDL analyzer, November 1990.
  16. Terazosin Hypertension Experience Trial, Phase IV 1990.
  17. Hypertensive Mid-Life Male Clinical Evaluation Phase IV trial, 1991.
  18. Dyna Circ Assessment Trial Analysis Phase IV trial, 1991.
  19. Cholestech evaluation of LDX triglyceride analyzer, 1991
  20. Prosom Evaluation Program, Phase IV, 1992
  21. Dyna Circ Dynamics trial in Special Populations, Phase IV, 1992.
  22. Sandoz Fluvastatin Phase III, 1993.
  23. Insomnia Treatment Study, Upjohn, Phase IV, 1993
  24. Lilly IOAH Insulin Analog Protocol, Global Phase II and III, 1993.
  25. Satellite site for The Diabetes Prevention Trial of Type I Diabetes (DPT-I), affiliated with Stanford University Research Center, 1994-current
  26. Lilly Lispro study F3Z-MC-IOBX "Insulin Lispro vs. Humulin R Delivered in 1.5 mL Pen." Phase III, 1994-95, Lilly
  27. Evaluation of Glucose Determinations from Venous Blood and Fluid Collected by Iontophoresis, Cygnus Therapeutic Systems, Developmental studies, 1994.
  28. Multicenter Open-Label Study of Terbinafine, Sandoz, Phase III, 1995-
  29. A Placebo-Controlled Safety and Efficacy Study of Pimagedine in Patients with Type II Diabetes Mellitus and Overt Diabetic Nephropathy. Marion Merrell Dow, Phase II and III, 1995.
  30. P.R.O.T.E.C.T. Precose: Resolution of Optimal Titration to Enhance Current Therapies trial. Phase III-IV, 1995 - Bayer
  31. Protocol for a randomized, double-blind, placebo controlled, cross-over study of the analgesic efficacy and safety of topical lidocaine patches and lidocaine gel in painful diabetic neuropathy. Phase II-III. Hind Health Care, Inc. 1996-
  32. A double blind randomized placebo-controlled study to evaluate the renal protective effects of Losartan in patients with NIDDM & nephropathy, Phase III - IV, Merck 1997
  33. Correlation of blood glucose with iontophoretic extraction using the GlucoWatch in subjects with diabetes. Phase II Cygnus 1997.
  34. Evaluation of the Glucometer DEX Stripless Monitoring Systems. Phase I - Bayer Diagnostics 1997.
  35. Evaluation of a reduced pain blood sampling device. Phase I - Mercury Diagnostics 1997.
  36. 28-week multicenter, controlled, randomized, open-label clinical trial comparing HOE-901 insulin with NPH human insulin in subjects with type 1 diabetes (HOE-901/3004). Phase III-Hoechst Marion Roussel, 1997.
  37. 28-week multicenter, controlled, randomized, open-label clinical trial comparing HOE-901 insulin with NPH human insulin in subjects with type 2 diabetes (HOE-901/3006). Phase III-Hoechst Marion Roussel, 1997.
  38. 16-week multicenter, controlled, randomized, open-label clinical trial comparing HOE 901 insulin and NPH human insulin in subjects with type 1 diabetes treated with insulin Lispro (HOE 901/3005). Phase III-Hoechst Marion Roussel, 1997.
  39. An Open-Label, Subject-Controlled Clinical Study of Mercury Diagnostics Blood Glucose Measurement System ("Mercury Gold Systems"). Phase III Mercury Diagnostics, 1997.
  40. Clinical Evaluation of Extremely Small Blood Volume Glucose Test Strips which Fill Capillary Blood from Arm Lancet Stick, TheraSense, Phase II, 1998.
  41. Insulin Delivery Using a New Lilly 3.0 mL Disposable Pen Device, Protocol F3Z-US-IOHE Phase IV, Eli Lilly, 1998-2001
  42. Efficacy & Safety of Inhaled Compared with Subcutaneous Human Insulin Therapy in Subjects with Type 1 Diabetes Mellitus: A Six-month, Outpatient, Parallel Comparative Trial, Protocol 217-106, Phase III, Pfizer, 1998-2003
  43. Efficacy & Safety of Inhaled Compared with Subcutaneous Human Insulin Therapy in Subjects with Type 2 Diabetes Mellitus: A Six-month, Outpatient, Parallel Comparative Trial, Protocol 217-108, Phase III, Pfizer, 1998-2003
  44. Evaluating Insulin Syringe Brand Preference Among Consumers: A Multi-Center Study, Protocol BDCHC-DHC-98-23, Phase IV, Becton-Dickenson, 1999.
  45. Repaglinide (Prandin) Combined with Bedtime Insulin NPH (Novolin N) in Comparison to Insulin in any Mixture Twice a Day for the Treatment of Type 2 Diabetes Patients Previously On Insulin Monotherapy; a Randomized Open-Label Study, Protocol AGEE-2022, Phase IV, Novo Nordisk, 1999

46. Preliminary Evaluation of the Kumetrix, Inc. Minimally Invasive Glucose Test; Elements of Pain Perception, Needle Breakage, Blood Volume, Glucose Analysis, Development Study, 1999.
47. A Multicenter, Randomized, Double-Blind, Parallel-Group, Clinical Evaluation of Oral GI262570 Sodium Tablets (2.5 mg, 5 mg and 7.5 mg GI262570) in Combination With Metformin For 26 Weeks Duration in Subjects with Type 2 Diabetes Mellitus Who Are Inadequately Controlled on a Maximum Dose of Metformin, PPA300002, Phase III, GlaxoWellcome, 1999.
48. OTC Clinical Evaluation of DRx®HbA1c, Protocol 083099-HbA1c, Metrika, Inc., 1999.
49. A Study To Compare The Performance Of The Glucowatch® Automatic Glucose Biographer Using Autosensors From Two Different Manufacturing Sites In Subjects With Diabetes Mellitus. GMS-PAC-052, Cygnus, Inc., 2000
50. "Omapatrilat Cardiovascular Treatment Assessment Versus Enalapril (Octave), BMS, Phase III, 2000
51. Long Term Safety of EXUBERA (inhaled insulin):Extension of Therapy in Subjects with Type 1 or Type 2 Diabetes Mellitus Completing Phase III Randomized Treatment Trials. Pfizer Inc. 2000-
52. Prospective Evaluation of the New HFE-71L-14457 Lubrication with 29 Gauge, 12-7mm, ½ cc and 3/10 cc Insulin Syringes in Adults. Becton Dickinson & Company, 2001.
53. 12-Week, Multinational, Multicenter, Controlled, Open, 1:1:1 Randomized, Parallel Clinical Trial to Assess Noninferiority Between Pre- and Post-Meal Administration of HMR 1964 and Pre-Meal Regular Human Insulin in Subjects with Type 1 Diabetes Mellitus Receiving Insulin Glargine as the Basal Insulin Therapy. Aventis Pharmaceuticals, Inc. 2001
54. Systolic and Pulse Pressure Hemodynamic Improvement by Restoring Elasticity: The Sapphire Study. Alteon, Inc. Phase II, Alteon, Inc, Phase II, 2001-2003
55. Systolic and Pulse Pressure Hemodynamic Improvement by Restoring Elasticity: The Sapphire Study-Extension Safety Study, ALT-711-0215, Alteon, Inc. Phase II, 2002-2003
56. KOS Pharmaceuticals Inc. & Dupont Pharmaceuticals Company, "The IMPACT Study-The Impact of Medical Subspecialty on Patient Compliance to Treatment" ICON Clinical Research, Inc. 2001
57. Point-of-Care %HbA1c Testing- A1cNow™, METRIKA, INC. 2001-2003
58. A Market Research Study of the Glucowatch® Automatic Glucose Biographer for Use to Detect Trends and Track Patterns in Glucose Levels in Adults with Diabetes. Cygnus™ 2001.
59. Preliminary Evaluation of the Phoenix Bioscience IPD Sampling System and Glucose Test; Elements of Pain Perception, Blood Volume, Glucose Analysis, PHOENIX BIOSCIENCE, INC 2002-
60. GOAL A1c Impact of Point-Of-Care vs. Laboratory Testing Of Hemoglobin A1c (HbA1c) And Intense vs. Standard Monitoring Of Titration Algorithm Adherence On Glycemic Control In Type 2 Diabetes Subjects, Who Are Inadequately Controlled On Oral Anti-Hyperglycemic Therapy, And Starting Lantus® (Insulin Glargine [rDNA Origin] Injection): A 2X2, Randomized, Open-Label Trial. Aventis Pharma 2002-2003.
61. A Phase 3B, Multicenter, Open-Label Study Investigating the Clinical Utility and Safety of Pramlintide in Subjects With Type 1 and Type 2 Diabetes Mellitus Who Have Not Achieved Glycemic Targets With Insulin Therapy, Amylin 2003-
62. Evaluation of the Phoenix Bioscience IPD Sampling System and Glucose Test; Elements of Pain Perception, Blood Volume, Glucose Analysis, PHOENIX BIOSCIENCE, INC 2003
63. A Multicenter, Double-Blind, Randomized, Parallel Group, 6-Week Study to Evaluate the Efficacy and Safety of Ezetimibe/Simvastatin Combination Tablet Versus Atorvastatin in Patients With Hypercholesterolemia, Merck 2003-3004
64. A Multicenter, Double-Blind, Placebo-Controlled, Randomized Study of the Safety of TAK-550 in the Treatment of Patients with Type 2 Diabetes Mellitus, Takeda, 2003-2005
65. A Multicenter, Double-Blind, Randomized, Parallel-Group Study to Compare the Effect of 24 Weeks Treatment with LAF237 (50 mg qd or bid) to Placebo as Add-On Therapy in Patients with Type 2 Diabetes Inadequately Controlled with Metformin Monotherapy, Novartis 2004-2006, Phase III
66. A 28-Week Extension to a Multicenter, Double-Blind, Randomized, Parallel-Group Study to Compare the Effect of 24 Weeks Treatment with LAF237 (50 mg qd or bid) to Placebo as Add-On Therapy in Patients with Type 2 Diabetes Inadequately Controlled with Metformin Monotherapy, Novartis 2004-2006, Phase III.
67. A Multicenter, Double-Blind, Randomized, Parallel-Group Study to Compare the Effect of 24 Weeks Treatment with LAF237 (50 mg qd or bid) to Placebo as Add-On Therapy to Pioglitazone 45 mg qd in Patients with Type 2 Diabetes Inadequately Controlled with Thiazolidinedione Monotherapy, Novartis 2004-2006, Phase III
68. A 28-Week Extension to a Multicenter, Double-Blind, Randomized, Parallel-Group Study to Compare the Effect of 24 Weeks Treatment with LAF237 (50 mg qd or bid) to Placebo as Add-On Therapy to Pioglitazone 45 mg qd in Patients with Type 2 Diabetes Inadequately Controlled with Thiazolidinedione Monotherapy, Novartis 2004-2006, Phase III.

69. A Multicenter, Double-Blind, Randomized, Parallel-Group Study to Compare the Effect of 24 Weeks Treatment with LAF237 (50 mg qd or bid) to Placebo as Add-On Therapy to Glimepiride in Patients with Type 2 Diabetes Inadequately Controlled with Sulfonylurea Monotherapy, Novartis 2004-2006, Phase III.
70. A 28-Week Extension to a Multicenter, Double-Blind, Randomized, Parallel-Group Study to Compare the Effect of 24 Weeks Treatment with LAF237 (50 mg qd or bid) to Placebo as Add-On Therapy in to Glimepiride in Patients with Type 2 Diabetes Inadequately Controlled with Sulfonylurea Monotherapy, Novartis 2004-2006, Phase III.
71. A Multicenter, Double-Blind, Randomized, Parallel-Group Study to Compare the Effect of 24 Weeks Treatment with LAF237 50 mg bid to Placebo as Add-On Therapy in Patients with Type 2 Diabetes Treated with Insulin, Novartis 2004-2006
72. A 28-Week Extension to a Multicenter, Double-Blind, Randomized, Parallel-Group Study to Compare the Effect of 24 Weeks Treatment with LAF237 50 mg bid to Placebo as Add-on Therapy in Patients with Insulin, Novartis 2004-2006
73. An International Prospective Observational Registry in Subjects at Risk of Atherothrombotic Events. The REACH REGISTRY, Bristol-Myers Squibb/Sanofi Pharmaceutical Partnership, 2004-2006
74. Protocol-EFC5826 (CRESCENDO)-Randomized, multinational, Multicenter, double-blind, placebo-controlled, two-arm parallel group trial of Rimonabant 20-mg OD for reducing the risk of major cardiovascular events in abdominally obese patients with clustering risk factors, Sanofi-Aventis, 2006-Phase III
75. A Multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the effects of aliskiren on proteinuria when added to standardized Losartan therapy and optimal antihypertensive therapy in patients with hypertension and Type 2 diabetes mellitus, Novartis, 2006-, Phase III. Protocol number CSPP100C2201
76. Protocol #: PHS1149-PROT201, Phase 2a, Randomized, Double-blind, Placebo-controlled, Multi-Center Study to Examine Safety and Establish Proof of Concept with PHX1149 in Patients with Type 2 Diabetes Mellitus, Phenomix Corporation 2006-
77. Trial ID: NN304-1720. Impact of a Self-Adjusted Titration Guideline in Subjects with Type 2 Diabetes Mellitus: A 6-Month, Multicenter, Open-Label, Randomized, Parallel-Group, Treat-to-Target of the Efficacy and Safety of Levemir® (insulin detemir [rDNA origin] injection). The PREDICTIVE™ 303 Study, Novo Nordisk, 2006-, Phase IV
78. An 8-week, Multicenter, randomized, double-blind, parallel-group study to evaluate the efficacy and safety of the combination of valsartan/HCTZ/amlodipine compared to valsartan/HCTZ, valsartan/amlodipine, and HCTZ/amlodipine in patients with moderate to severe hypertension, Novartis 2006-
79. Protocol ACD06-072 User Evaluation of the FreeStyle Navigator™ Continuous Glucose Monitoring System, Abbott Diabetes Care, 2007
80. A Phase II, randomized, double-blind, parallel-design study comparing efficacy and safety of VI-0521 to placebo in the Glycemic management of obese diabetic adults, Vivus, Inc, 2007-
81. Protocol HRA26-755A2-3, Validation Study for Two Measures regarding Insulin Therapy (EAITQ and EWITQ), Eli Lilly, 2007.

#### Additional Activities

1. National Advisory Board on Vulvovaginal Candidiasis, 1996
2. Advisory Board for Secondary Prevention of Coronary Artery Disease, 1996
3. Advisory Board for Clinical Use of Lispro Insulin, 1996
4. Interstate Postgraduate Medical Association of North America  
President Elect, 1995-1996  
**President**, 1996-1997  
Skyline Medical Assn. president
5. Member Vascular Biology Working Group, 1999-present
6. California Pan American Medical Society, President, 2000-2003
7. California Pan American Medical Society, Board of Directors, 2003-
8. Therafuse Inc, advisory board
9. Advisory Board, Amaryl, 2004-6
10. Advisory Board, Lantus 2004-6
11. Lilly/Alkermes Inhaled Insulin Clinical Advisory Board
12. Advisory Board Aventis, Exubera insulin 2004-6

13. Advisory Board, Mannkind Inhaled insulin 2006-current
14. Global Inhaled Insulin Advisory Board, Lilly/Alkermes, 2006-current
15. Consultant to Vivus
16. Consultant to Valeritas
17. Board of Directors, California Chapter, American Assn. Of Clinical Endocrinology, 2006-present
18. Ministry of Health, United Arab Emirates 1996-current

#### Faculty Positions

1. National Teaching Faculty for Changing the Natural History of Coronary Artery Disease, 1995-
2. National Teaching Faculty for Lipid Management in Clinical Practice, 1995-
3. National Diabetes Education Initiative for Health Care Professionals, 1997-
4. Lipid Speakers Bureau Western Region 1997-
5. National Obesity Management Leadership Conference, member 1996-
6. National Diabetes Faculty, 1997-
7. New Insights in Lipid Management, National Faculty 1997
8. Cardiovascular Risk Intervention: Western Working Group, 1997-
9. National Lipid Education Council 1997-2003

#### Speaking

Dr. Bohannon has been speaking internationally since 1978. Venues have included Germany, Canada, Italy, Korea, Taiwan, Thailand, the Philippines, the United Arab Emirates and the United Kingdom. She has lectured yearly for 1 or 2 weeks in the UK, at the invitation of the Postgraduate Tutor program of the National Health Service as well as other sponsors, throughout England, Scotland and Ireland. She also has been keynote speaker at many symposia in the United States and gives 100 CME Grand Rounds or other talks yearly.

#### Biotech and Analyst Consultancies

Primary Insight (a unit of Bear Stearns, a leading Wall Street investment bank) 2006-current  
 Society of Industry Leaders (Standard and Poore's Vista) 2005- current  
 MEDACORP 2004-current  
 ePocrates Honors Advocate 2006-current  
 Clinical Advisors 2004-current  
 Gerson Lehrman Group 2002-current